CRP and metabolic syndrome: Specifically, in patients with the metabolic syndrome and newly-diagnosed-hypertension, Shimbakuro and colleagues demonstrated a 10% (approximate) 24-week reduction in VAT that was accompanied by improved insulin sensitivity and glucose tolerance, higher adiponectin levels, and decreased C-reactive protein (CRP) [15].